From December @ to February @ , @ prostate cancer patients scheduled for intensity-modulated radiotherapy ( @ Gy in @ fractions ) using fiducial marker-based position verification were randomly assigned to receive magnesium oxide ( @ mg twice a day ) or placebo during radiotherapy .